Liquidity and Management's Plans - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		12 Months Ended		1 Months Ended		3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	0 Months Ended	3 Months Ended
	Jan. 31, 2014	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Apr. 30, 2014 Subsequent Event [Member]	Apr. 30, 2014 Subsequent Event [Member] Midcap warrant [Member]	Mar. 31, 2014 Endo License and Development Agreement [Member]	Dec. 31, 2013 Endo License and Development Agreement [Member]	Mar. 31, 2014 Meda License Development and Supply Agreement [Member]	Dec. 31, 2013 Meda License Development and Supply Agreement [Member]	Feb. 07, 2014 Definitive Securities Purchase Agreement [Member]	Mar. 31, 2014 Definitive Securities Purchase Agreement [Member]
Liquidity and Management's Plans [Line Items]
Proceeds from issuance of common stock	$ 3,900,000	$ 3,900,000										$ 58,200,000	$ 58,200,000
Contract revenue under the Endo agreement		11,200,000
Research and development reimbursements under the Endo agreements		8,451,979						8,500,000	2,800,000
Net royalties under the Meda agreements		953,990								300,000	1,800,000
Exercise of Common Stock options and warrants		2,559,724		400,000
Exercise of common stock warrants		2,575,001				1,400,000
Net proceeds from secured loan facility from Midcap				19,800,000
Contract revenue from licensing and supply agreement				300,000
Common stock exercised							283,871
Cash and cash equivalents		88,199,418	49,666,908	23,175,809	63,189,307
Cash from operations		611,196	(13,522,399)
Stockholders' equity		$ 64,614,109		$ (812,351)	$ 800,000